Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Utilization and Clinical Outcomes Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Jing-Zhou Hou, Rushir Choksi, Gregory A. Maglinte, Anupama Vasudevan, Anna Rui, Brandon Wang, Hoa Pham, Ann Lasn, Simon Blanc

Blood (2024) 144 (Supplement 1): 2353.

https://doi.org/10.1182/blood-2024-207760

Published: 2024

Journal Articles

Treatment-Emergent Cardiovascular Events Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Treated with Bruton's Tyrosine Kinase Inhibitors (BTKi)

Jing-Zhou Hou, Rushir Choksi, Anupama Vasudevan, Anna Rui, Poras Davé, Mike Gart, Brandon Wang, Prateesh Varughese, Simon Blanc

Blood (2024) 144 (Supplement 1): 3253.

https://doi.org/10.1182/blood-2024-199765

Published: 2024

Journal Articles

Hematologic Improvement Experienced By Pacritinib-Treated Patients with Myelofibrosis in Real-World Clinical Settings

Michael Marrone, Lisa Morere, Abiola Oladapo, Purvi Suthar, Teena Sura, Anupama Vasudevan, Michael Vredenburg, Jia Zeng, Raajit Rampal, John O. Mascarenhas

Blood (2024) 144 (Supplement 1): 3814.

https://doi.org/10.1182/blood-2024-210826

Published: 2024

Journal Articles

Real-World Treatment Patterns and Blood Count Control in Patients with Polycythemia Vera Who Switched from Hydroxyurea to Ruxolitinib

Naveen Pemmaraju, Jingbo Yu, Anupama Vasudevan, Husain Qureshi, Evan M. Braunstein, Aleksander L. Chojecki

Blood (2024) 144 (Supplement 1): 3813.

https://doi.org/10.1182/blood-2024-205193

Published: 2024

Journal Articles

Real-Word Effectiveness of Pacritinib in Patients with Myelofibrosis Who Have Thrombocytopenia and Anemia

Raajit Rampal, Michael Marrone, Lisa Morere, Abiola Oladapo, Purvi Suthar, Teena Sura, Anupama Vasudevan, Michael Vredenburg, Jia Zeng, John O. Mascarenhas

Blood (2024) 144 (Supplement 1): 6649.

https://doi.org/10.1182/blood-2024-210274

Published: 2024

Journal Articles

Early Anemia Response in Patients with Myelofibrosis Treated with Pacritinib in Real-Word Clinical Settings

John O. Mascarenhas, Michael Marrone, Lisa Morere, Abiola Oladapo, Purvi Suthar, Teena Sura, Anupama Vasudevan, Michael Vredenburg, Jia Zeng, Raajit Rampal

Blood (2024) 144 (Supplement 1): 6650.

https://doi.org/10.1182/blood-2024-210598

Published: 2024

Journal Articles

Assessing Adoption of Standard of Care and Comparing Clinical and Demographic Differences in First-Line (1L) Treatment (Tx) of Chronic Lymphocytic Leukemia (CLL)

Jing-Zhou Hou, Michael Gart, Anupama Vasudevan, Harvey I. Katzen, Rushir Choksi, Simon Blanc

Blood (2023) 142 (Supplement 1): 130.

https://doi.org/10.1182/blood-2023-178685

Published: 2023

Journal Articles

An Analysis of Ruxolitinib Dosing for Myelofibrosis in Real-World Practice

James M. Rossetti, Rushir Choksi, Purvi Suthar, Phoebe Davis, Anupama Vasudevan, Poras Dave, Varun Vaidya, Brandon Wang, Harvey I. Katzen

Blood (2023) 142 (Supplement 1): 5186.

https://doi.org/10.1182/blood-2023-179402

Published: 2023

Journal Articles

Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Patterns Among Patients with Chronic or Small Lymphocytic Leukemia (CLL/SLL) in US Community Oncology Practices

Jing-Zhou Hou, Simon Blanc, Gregory A Maglinte, Anupama Vasudevan, Anna Rui, Michael Gart, Hoa Pham, Lindsay Aton, Brandon Wang, Rushir Choksi

Blood (2023) 142 (Supplement 1): 5163.

https://doi.org/10.1182/blood-2023-174915

Published: 2023

Journal Articles

A Patient-Centered Programmatic Approach for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in the US Community Oncology Setting

James M. Rossetti, Rushir Choksi, Anupama Vasudevan, Simon Blanc, Dawn Brenneman, Brandon Wang, Peter McMahon, Jason Beal, Teraneh Z. Jhaveri, Mellissa Williamson, Cosmina Hogea

Blood (2023) 142 (Supplement 1): 5101.

https://doi.org/10.1182/blood-2023-186836

Published: 2023

NARROW

Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Utilization and Clinical Outcomes Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Treatment-Emergent Cardiovascular Events Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Treated with Bruton's Tyrosine Kinase Inhibitors (BTKi)

Hematologic Improvement Experienced By Pacritinib-Treated Patients with Myelofibrosis in Real-World Clinical Settings

Real-World Treatment Patterns and Blood Count Control in Patients with Polycythemia Vera Who Switched from Hydroxyurea to Ruxolitinib

Real-Word Effectiveness of Pacritinib in Patients with Myelofibrosis Who Have Thrombocytopenia and Anemia

Early Anemia Response in Patients with Myelofibrosis Treated with Pacritinib in Real-Word Clinical Settings

Assessing Adoption of Standard of Care and Comparing Clinical and Demographic Differences in First-Line (1L) Treatment (Tx) of Chronic Lymphocytic Leukemia (CLL)

An Analysis of Ruxolitinib Dosing for Myelofibrosis in Real-World Practice

Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Patterns Among Patients with Chronic or Small Lymphocytic Leukemia (CLL/SLL) in US Community Oncology Practices

A Patient-Centered Programmatic Approach for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in the US Community Oncology Setting

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only